Summit Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $-235 |
Gross Profit | -19 | -20 | -27 | -840 |
EBITDA | -53,515 | -57,422 | -40,538 | -33,297 |
EBIT | -53,535 | -57,442 | -40,565 | -33,902 |
Net Income | -56,254 | -60,385 | -43,473 | -36,567 |
Net Change In Cash | 0 | 0 | 0 | -235 |
Free Cash Flow | -30,355 | -32,912 | -30,138 | -19,461 |
Cash | 93,775 | 28,754 | 61,294 | 71,425 |
Basic Shares | 726,656 | 707,904 | 701,785 | 701,660 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $704 | $1,809 | $860 |
Gross Profit | -2,050 | -1,809 | 1,809 | 860 |
EBITDA | 1,001 | -52,630 | -83,731 | -37,134 |
EBIT | -1,049 | -55,144 | -86,186 | -39,137 |
Net Income | -614,928 | -74,381 | -86,147 | -52,697 |
Net Change In Cash | 0 | 704 | 1,809 | 860 |
Free Cash Flow | -76,888 | -42,206 | -72,893 | -48,532 |
Cash | 71,425 | 348,607 | 71,791 | 66,417 |
Basic Shares | 619,646 | 193,336 | 92,239 | 69,524 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.08 |
2024-06-30 | -$0.09 |
2024-03-31 | -$0.06 |
2023-12-31 | -$0.05 |
